<DOC>
	<DOCNO>NCT00770367</DOCNO>
	<brief_summary>SPECIFIC AIMS 1 . To determine whether pioglitazone reduce level asymmetric dimethylarginine ( ADMA ) patient diabetes . 2 . To determine whether nitric oxide ( NOx ) product increase pioglitazone treatment . 3 . To determine whether pioglitazone reduces oxidative stress ( F2-isoprostanes ) .</brief_summary>
	<brief_title>Pioglitazone Serum Asymmetric Dimethylarginine ( ADMA ) Patients With Diabetes</brief_title>
	<detailed_description>The primary purpose study determine whether treatment pioglitazone reduce serum level asymmetric dimethylarginine ( ADMA ) patient adult diabetes . Recent research find elevate serum ADMA associate increase cardiovascular event mortality , particularly people diabetes ( Boger 2005 , Zoccali 2006 , Ueda 2007 ) . ADMA , mediate nitric oxide ( NO ) availability , may trigger pro-atherogenic effect . High plasma concentration substance associate intima-media thickening , leave ventricular hypertrophy all-cause cardiovascular mortality patient end-stage renal disease , associate increase cardiovascular event patient diabetes ( Kryzazanowska 2007 ) . The result high level ADMA reduce output NO increase vasoconstriction , increase inflammation , interfere endothelial function . Preliminary study indicate pioglitazone may reduce ADMA level , thus low cardiovascular risk.Thus , protocol test whether pioglitazone reduce ADMA level adult patient diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>N , N-dimethylarginine</mesh_term>
	<criteria>Adults age 4075 yearsofage , nonpregnant Informed consent History type 2 Diabetes Mellitus Stable weight last 3 month ( change great +5 % body weight ) ADMA &gt; 0.50 ÂµM/L ( mean nondiabetic reference group ) ( Devangelio 2007 ) On stable medical therapy least 3 month A work telephone Any history know coronary heart disease , include history congestive heart failure , myocardial infarction , coronary revascularization , stroke Pregnancy Chronic kidney disease , serum creatinine &gt; 2.0mg/dl , chronic liver disease , uncontrolled hypertension ( &gt; 160/100 ) . Current participation formal weight loss program planning start program next 3 month Collagen vascular disease , infection , inflammatory condition Electrocardiogram ( EKG ) evidence ischemia infarction Macular edema ( swell back eye ) , recent excessive weight gain ( 5 % weight 30 day ) , elevate liver function test &gt; 2.5 X upper limit , history osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Cardiovascular risk</keyword>
	<keyword>biological marker</keyword>
</DOC>